What is the official website of MENARINI Group ?

The official website of MENARINI Group is https://www.menarini.com.

What is MENARINI Group's cybersecurity risk score?

MENARINI Group has an AI-generated cybersecurity risk score of 784 out of 1000, indicating a Fair security posture according to Rankiteo's assessment.

How many security incidents has MENARINI Group experienced?

According to Rankiteo, MENARINI Group currently holds 0 security badges, indicating that no recognized compliance certifications are currently verified for the organization.

Has MENARINI Group been affected by any supply chain cyber incidents ?

According to Rankiteo, MENARINI Group has not been affected by any supply chain cyber incidents, and no incident IDs are currently listed for the organization.

Does MENARINI Group have SOC 2 Type 1 certification ?

According to Rankiteo, MENARINI Group is not certified under SOC 2 Type 1.

Does MENARINI Group have SOC 2 Type 2 certification ?

According to Rankiteo, MENARINI Group does not hold a SOC 2 Type 2 certification.

Does MENARINI Group comply with GDPR ?

According to Rankiteo, MENARINI Group is not listed as GDPR compliant.

Does MENARINI Group have PCI DSS certification ?

According to Rankiteo, MENARINI Group does not currently maintain PCI DSS compliance.

Does MENARINI Group comply with HIPAA ?

According to Rankiteo, MENARINI Group is not compliant with HIPAA regulations.

Does MENARINI Group have ISO 27001 certification ?

According to Rankiteo,MENARINI Group is not certified under ISO 27001, indicating the absence of a formally recognized information security management framework.

Which industry does MENARINI Group operate in ?

MENARINI Group operates primarily in the Pharmaceutical Manufacturing industry.

How many employees does MENARINI Group have ?

MENARINI Group employs approximately 12,720 people worldwide.

Does MENARINI Group own any subsidiaries ?

MENARINI Group presently has no subsidiaries across any sectors.

How many LinkedIn followers does MENARINI Group have ?

MENARINI Group's official LinkedIn profile has approximately 423,250 followers.

What is the NAICS classification code for MENARINI Group ?

MENARINI Group is classified under the NAICS code 3254, which corresponds to Pharmaceutical and Medicine Manufacturing.

Does MENARINI Group have a Crunchbase profile ?

No, MENARINI Group does not have a profile on Crunchbase.

Does MENARINI Group have a LinkedIn profile ?

Yes, MENARINI Group maintains an official LinkedIn profile, which is actively utilized for branding and talent engagement, which can be accessed here: https://www.linkedin.com/company/menarini.

How many cybersecurity incidents has MENARINI Group experienced ?

As of June 22, 2026, Rankiteo reports that MENARINI Group has not experienced any cybersecurity incidents.

How many peer or competitor companies does MENARINI Group have ?

MENARINI Group has an estimated 5,695 peer or competitor companies worldwide.

NEWRankiteo Cyber Underwriting Desktop - Score, price, and bind from your desktop

WindowsmacOSLinux

Download

Badge your company to reduce your risk score and your cyber insurance costs!

Link verified badges to your company page to build trust with insurers and customers.

Apply now and get your badge!

Internal validation & live display

Insurers and partners see a safer profile

Faster underwriting decisions

Trusted by insurers. Chosen by leaders.

Proud contributor to the Society of Actuaries.

MENARINI Group

Boost Score +25 with badge (5 left)

784

/1000

Fair

809

/1000

Good

MENARINI Group Vendor Cyber Rating & Cyber Score

menarini.com

Add Your Compliance Badge

The Menarini Group is a leading international pharmaceutical and diagnostics company, present in 140 countries worldwide, with a turnover of 4,37 Billion euro and more than 17,000 employees. With 9 centers for Research & Development, Menarini’s products are present in the most important therapeutic areas, including cardiology, oncology, gastroenterology, pneumology, infectious diseases, diabetes, and anti-inflammatory/analgesics. The Group’s pharmaceutical production is carried out in its 18 manufacturing plants, which produce over 609 million packets of product a year and distribute them to five continents. Menarini’s pharmaceutical production, in line with the highest quality standards, provides an ongoing contribution to the health

MENARINI Group A.I CyberSecurity Scoring

Scoring History

MENARINI Group

MENARINI Group CyberSecurity News & History

Past Incidents

Attack Types

Entity

Type

Severity

Impact

Seen

Blog Details

Supply Chain Source

Incident Details

View

No data available

Loading…

A.I.

MENARINI Group Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Actual

Prediction

Incident Predictions locked

Access Monitoring Plan

A.I Risk Score Likelihood 3 - 6 - 9 months

Actual

Prediction A

Prediction B

Prediction C

Prediction D

A.I. Risk Score Predictions locked

Access Monitoring Plan

Loading…

Underwriter Stats for MENARINI Group

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for MENARINI Group in 2026.

Incidents vs All-Companies Average (This Year)

No incidents recorded for MENARINI Group in 2026.

Incident Types MENARINI Group vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for MENARINI Group in 2026.

Incident History - MENARINI Group (X = Date, Y = Severity)

Loading…

SUBSIDIARY

MENARINI Group Subsidiaries

Parent Company

MENARINI Group

Pharmaceutical Manufacturing

Website: https://www.menarini.com

Company Size: 10,001+ employees

No subsidiary data available for this company.

Loading…

MENARINI Group Similar Companies

MSD

msd.com

At MSD, known as Merck & Co., Inc., Rahway, NJ, USA in the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit www.msd.com and connect with us on Facebook, Instagram, Twitter, and YouTube.

Intas Pharmaceuticals

intaspharma.com

Intas is one of the leading multinational pharmaceutical formulation development, manufacturing, and marketing organization in the world. It has been growing at 19% CAGR and crossed the $2.5 billion mark in the past financial year. The company has set up a network of subsidiaries, under the name Accord Healthcare in the EU, US, Canada, SA, Australia, APAC as well as CIS & MENA regions. Intas is present in 85+ countries, with more than 70% of its revenue coming from global business. Currently ranked 6th in the Indian pharmaceutical market, it’s the largest privately owned Indian generic pharma company. Intas has established leadership in key therapeutic segments like CNS, Cardio, Diabeto, Gastro, Urology, Oncology & Animal Health in India. We are among the top 10 generic players in the highly regulated markets of EU, US & UK. Intas operates 17 advanced formulations, R&D, and distribution facilities, of which 10 are in India and the rest in the UK, Mexico & Greece with the help of our 23,000+ Human Capital. Between them, the facilities are accredited by global regulators such as USFDA, EMA, MHRA, TGA, and others. The company invests ~6-7% of its revenues in R&D and has over 10,000 product registrations worldwide with a strategic pipeline of 300+ high-value FTF/FTM, Biosimilars, and NDDS products. Intas' highly advanced EU-GMP Certified Biopharma division is fueled by a mission to provide affordable “Biosimilars for Billions” across niche segments such as oncology, auto-immune, ophthalmology, nephrology, rheumatology, and hormone-based therapies. The Plasma Fractionation Unit of Intas Pharmaceuticals is a pioneer in manufacturing plasma-derived therapeutics. It houses a full-fledged R&D lab and a state-of-the-art WHO-GMP-certified manufacturing facility complemented with a GLP-compliant QC lab. Our values of Innovation, Customer Delight, Ownership & Collaboration, Performance Focus & Care for Society are the driving forces toward excellence.

Novartis

cb novartis.com

Novartis is an innovative medicines company. Every day, working to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 250 million people worldwide. Find out more at https://www.novartis.com See our community guidelines: https://go.novartis.social/3Nboxki

Fresenius Kabi

fresenius-kabi.com

As a global healthcare company, Fresenius Kabi is Committed to Life. The company’s products, technologies, and services are used for the therapy and care of critically and chronically ill patients. With over 41,000 employees and present in over 100 countries, Fresenius Kabi’s expansive product portfolio focuses on providing access to high-quality and lifesaving medicines and technologies. In Biopharma, Fresenius Kabi offers cutting-edge biosimilars for autoimmune diseases and oncology. With leading market positions in Clinical Nutrition, a broad portfolio of enteral and parenteral products makes a distinct difference in patients’ nutritional status. In MedTech, the company provides vital infusion pumps, cell and gene therapy devices, disposables, and more. Fresenius Kabi is the global leader in supplying blood collection bags and devices, supporting blood banks and healthcare facilities worldwide. The company’s I.V. Generics and Fluids for infusion therapy help save millions of lives every year, in emergency medicine, surgery, oncology, and intensive care. Fresenius Kabi takes a holistic approach to healthcare and uniquely combines experience, expertise, innovation, and dedication – making a difference in the lives of 450 million patients annually. With the #FutureFresenius strategy, the company is developing, producing, and selling new products and technologies and aspires to expand its position as a leading global provider of therapies, improve patient care, generate sustainable value for stakeholders – shaping the future of healthcare. Fresenius Kabi is an operating company of the Fresenius Group, founded in 1912, along with Helios and Quirónsalud. As ONE team, the companies in the Fresenius Group are committed to providing lifesaving and life-changing healthcare solutions on a global scale. User information & community guidelines: https://www.fresenius-kabi.com/social-media-terms-conditions Imprint: www.fresenius-kabi.com/imprint

Johnson & Johnson Innovative Medicine

cb jnj.com

At Johnson & Johnson Innovative Medicine, we innovate with purpose, to lead where medicine is going. The experiences of patients around the world inform and inspire our science-based innovations, which continue to change and save lives. Applying rigorous science with compassion, we confidently address the most complex diseases of our time and develop the potential medicines of tomorrow. We are continuously working to develop treatments, aspiring to find cures, pioneering the path from lab to life, and championing patients every step of the way. https://bit.ly/3reuMvK

Merck Group

merckgroup.com

This channel is not intended for U.S. and Canadian visitors. Merck operates in the U.S. and Canada as EMD Serono in Healthcare, MilliporeSigma in Life Science and EMD Electronics in Electronics. An unaffiliated and unrelated company, Merck & Co., Inc., Kenilworth, NJ, US holds the rights in the trademark MERCK in the U.S. and Canada. _______________________________ We are Merck, a leading global science and technology company headquartered in Germany. We are curious explorers, courageous pioneers, and ingenious inventors. Our colleagues across the globe love innovating with science and technology to enrich people’s lives with our solutions in Life Science, Healthcare, and Electronics. Together, we dream big and are passionate about caring for our rich mix of people, customers, patients, and the planet. We believe in the positive power of science and technology. It has determined our actions since 1668 and inspires us to continue researching for a future worth living. As a family-owned company with over 350 years of experience, we stand for sustainability, responsibility, and innovative strength. We take pride in being a diverse and inclusive company that values and fosters the talents and abilities of our employees. That's why we are always looking for curious minds that see themselves imagining the unimaginable with us. Work your Magic and join Merck. Legal Disclaimer: www.merckgroup.com/en/legal-disclaimer.html Data Privacy Declaration: www.merckgroup.com/en/privacy-statement

AbbVie

cb abbvie.com

AbbVie is a global biopharmaceutical company focused on creating medicines and solutions that put impact first — for patients, communities, and our world. We aim to address complex health issues and enhance people's lives through our core therapeutic areas: immunology, oncology, neuroscience, eye care, aesthetics and other areas of unmet need. Learn more about us at www.abbvie.com and review our community guidelines at https://www.abbvie.com/social-media-community-guidelines.html.

Parexel

parexel.com

Parexel is a leading global clinical research organization (CRO) providing insights-driven Clinical and Consulting solutions to the world’s life sciences industry. Leveraging deep local knowledge and a global breadth of clinical, regulatory and therapeutic expertise, our 24,000+ professionals worldwide work in partnership with biopharmaceutical leaders, emerging innovators and sites to design and deliver clinical trials with patients in mind — broadening access and making clinical research a care option for anyone, anywhere. Our proven track record spans 40+ years and drives us forward, advancing clinical research in healthcare’s most complex areas while harnessing innovation to drive efficiencies across every phase of the clinical development process. Our insights-driven approach, proven delivery and trusted execution are accelerating the delivery of life-changing treatments to patients — With Heart.™ We continue to earn recognition industrywide, including the 2025 Scrip Award for “Best Contract Research Organization – Full-Service Provider,” 2024 Fierce Biotech CRO Award for "Innovative Approaches to Patient-Centric Research" and the 2024 and 2023 Society for Clinical Research Sites (SCRS) Eagle Award. Community Guidelines Because Parexel’s social media channels are open to the general public and employees, we are not responsible for views expressed other than our own. However, we do not tolerate posts that are: • Abusive, harassing or threatening to others. • Defamatory, offensive, obscene, vulgar or depicting violence. • Hateful targeting by race/ethnicity, age, color, creed, religion, gender, sexual preference or orientation, nationality or political beliefs. • Sexually explicit or pornographic. • Fraudulent, deceptive, libelous, misleading or unlawful. • Referencing criminal or illegal activity. • Spamming. We reserve the right to remove comments that do not adhere to our guidelines and report users who violate the rules of our page.

Merck

merck.us

At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit www.merck.com. This site is intended for residents of the United States and Canada and their territories only. FLS: http://merck.us/3TKXNuZ

Loading…

NEWS

MENARINI Group CyberSecurity News

Latest updates, reports, and threat intel affecting the global network.

March 09, 2026 07:00 AM

Medidata Expands Partnership with The Menarini Group, Deploying Medidata’s Study Build AI Technology to Accelerate Global Oncology Pipeline

Fourteen-year collaboration enters a new phase as Menarini evolves its use of the Medidata Platform, combining established clinical...

Read Article

March 09, 2026 07:00 AM

Menarini nears €4.9 billion in 2025 and focuses on talent and AI as ‘giant’ players enter pharma

FLORENCE, Italy, March 09, 2026 (GLOBE NEWSWIRE) -- 2025 was a 'positive year” for Menarini, which is celebrating its 140th anniversary this...

Read Article

February 03, 2026 08:00 AM

Insilico Medicine Receives USD 5million Milestone Payment from Menarini Group Following First-in-Human (FIH) Achievement for MEN2501

Insilico Medicine ("Insilico"), a clinical-stage, generative artificial intelligence (AI)-driven biotechnology company, today announced that...

Read Article

January 13, 2025 08:00 AM

Firm Advises Insilico on Patent Matters Related to Exclusive Global License Agreement with Menarini Group

On January 10, 2025, leading international pharmaceutical and diagnostics company the Menarini Group and Stemline Therapeutics, Inc.,...

Read Article

January 13, 2025 08:00 AM

Menarini, Insilico Medicine deepen AI partnership with potential $550M deal

Drug discovery startup Insilico Medicine and Italian pharmaceutical company Menarini Group announced their second licensing agreement.

Read Article

May 05, 2020 07:00 AM

Menarini Group to buy Stemline Therapeutics in deal valued at $677m

Italian pharmaceutical and diagnostics company Menarini Group has signed a definitive agreement to acquire US-based Stemline Therapeutics...

Read Article

July 24, 2014 07:00 AM

Menarini Group Heirs Set To Inherit $10.4B, But The Tax Man Is After Them

Massimiliana Landini Aleotti and her three children, currently running Menarini, Italy's leading pharma company, are set to inherit an estimated fortune of $10...

Read Article

Loading…

CVE

Latest

Global CVEs (Not Company-Specific)

CVE-2026-12814

SUMMARY

A flaw has been found in Comfast CF-WR631AX V3 up to 2.7.0.8. This issue affects the function system of the file /cgi-bin/mbox-config?section=ping_config of the component API Endpoint. This manipulation of the argument destination causes os command injection. The attack is possible to be carried out remotely. The exploit has been published and may be used. The vendor was contacted early about this disclosure but did not respond in any way.

Published

Date2026-06-21

Updated

Date2026-06-21

RISK INFORMATION (Score: 6.3)

cvss2

Base Score: 6.5

Complexity: LOW

AV:N/AC:L/Au:S/C:P/I:P/A:P

cvss3

Base Score: 6.3

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:L/I:L/A:L

cvss4

Base Score: 2.1

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:L/UI:N/VC:L/VI:L/VA:L/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

3.4

Exploitability

2.8

REFERENCES

CVE-2026-12813

SUMMARY

A vulnerability was detected in activepieces up to 0.83.0. This vulnerability affects the function handleUrlFile in the library packages/server/engine/src/lib/variables/processors/file.ts of the component File URL Handler. The manipulation results in server-side request forgery. The attack can be executed remotely. The exploit is now public and may be used. The vendor was contacted early about this disclosure but did not respond in any way.

Published

Date2026-06-21

Updated

Date2026-06-21

RISK INFORMATION (Score: 6.3)

cvss2

Base Score: 6.5

Complexity: LOW

AV:N/AC:L/Au:S/C:P/I:P/A:P

cvss3

Base Score: 6.3

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:L/I:L/A:L

cvss4

Base Score: 2.1

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:L/UI:N/VC:L/VI:L/VA:L/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

3.4

Exploitability

2.8

REFERENCES

CVE-2026-12812

SUMMARY

A security vulnerability has been detected in Radware Cyber Controller up to 10.11.0. This affects an unknown part of the component HTML Report Generation. The manipulation leads to HTML injection. Remote exploitation of the attack is possible. The exploit has been disclosed publicly and may be used. The vendor was contacted early about this disclosure but did not respond in any way.

Published

Date2026-06-21

Updated

Date2026-06-21

RISK INFORMATION (Score: 3.5)

cvss2

Base Score: 4.0

Complexity: LOW

AV:N/AC:L/Au:S/C:N/I:P/A:N

cvss3

Base Score: 3.5

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:L/UI:R/S:U/C:N/I:L/A:N

cvss4

Base Score: 2.0

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:L/UI:P/VC:N/VI:L/VA:N/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

1.4

Exploitability

2.1

REFERENCES

CVE-2026-12811

SUMMARY

A weakness has been identified in kortix-ai suna up to 0.8.38. Affected by this issue is the function router.replace/router.push of the file apps/frontend/src/app/auth/page.tsx of the component Auth Endpoint. Executing a manipulation of the argument returnURL can lead to cross site scripting. The attack may be launched remotely. The exploit has been made available to the public and could be used for attacks. Upgrading to version 0.8.39 can resolve this issue. This patch is called f5dec7aa0c1b8fa0125938f292c0f2430ca75f6c. It is advisable to upgrade the affected component. The researcher explains: "The issue was fixed in v0.8.39 without notifying the wider user base via a security disclosure."

Published

Date2026-06-21

Updated

Date2026-06-21

RISK INFORMATION (Score: 4.3)

cvss2

Base Score: 5.0

Complexity: LOW

AV:N/AC:L/Au:N/C:N/I:P/A:N

cvss3

Base Score: 4.3

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:R/S:U/C:N/I:L/A:N

cvss4

Base Score: 2.1

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:P/VC:N/VI:L/VA:N/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

1.4

Exploitability

2.8

REFERENCES

CVE-2026-12810

SUMMARY

A security flaw has been discovered in Edimax BR-6478AC V2 1.23. Affected by this vulnerability is the function mp of the file /goform/mp of the component POST Request Handler. Performing a manipulation of the argument command results in command injection. The attack may be initiated remotely. The exploit has been released to the public and may be used for attacks. The vendor was contacted early about this disclosure but did not respond in any way.

Published

Date2026-06-21

Updated

Date2026-06-21

RISK INFORMATION (Score: 6.3)

cvss2

Base Score: 6.5

Complexity: LOW

AV:N/AC:L/Au:S/C:P/I:P/A:P

cvss3

Base Score: 6.3

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:L/I:L/A:L

cvss4

Base Score: 2.1

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:L/UI:N/VC:L/VI:L/VA:L/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

3.4

Exploitability

2.8

REFERENCES

Loading…

API

Access Data Using Our API

Get company history

curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'

Try It API Documentation Rapid

MEASURE

What Do We Measure ?

Incident

Finding

Grade

Digital Assets

Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.

These are some of the factors we use to calculate the overall score:

Network SecurityIdentify exposed access points, detect misconfigured SSL certificates, and uncover vulnerabilities across the network infrastructure.

SBOM (Software Bill of Materials)Gain visibility into the software components used within an organization to detect vulnerabilities, manage risk, and ensure supply chain security.

CMDB (Configuration Management Database)Monitor and manage all IT assets and their configurations to ensure accurate, real-time visibility across the company's technology environment.

Threat IntelligenceLeverage real-time insights on active threats, malware campaigns, and emerging vulnerabilities to proactively defend against evolving cyberattacks.

Rankiteo

By Rankiteo

★ ★ ★ ★ ★

View on G2.com

Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.

View latest plans →View all security reports →

MILESTONEG

Users
Love Us

Loading…